MedTrace Logo

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia

NCT06535113 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-05-08

No results posted yet for this study

Summary

The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.

Conditions

Interventions

OTHER

Clinical Practice

All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines. There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.

Sponsors & Collaborators

  • Azienda Ospedaliera Bianchi-Melacrino-Morelli

    collaborator OTHER

  • Ciceri Fabio

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-22
Primary Completion
2026-01-31
Completion
2026-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535113 on ClinicalTrials.gov